NASDAQ:VIRI Virios Therapeutics (VIRI) Stock Price, News & Analysis → How to Make 100X on the AI Boom (From InvestorPlace) (Ad) Free VIRI Stock Alerts $0.38 +0.03 (+8.55%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$0.35▼$0.3950-Day Range$0.31▼$0.5852-Week Range$0.28▼$2.42Volume166,188 shsAverage Volume314,241 shsMarket Capitalization$7.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Virios Therapeutics alerts: Email Address Virios Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.24% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.27) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.12 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Virios Therapeutics.Read more about Virios Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.24% of the outstanding shares of Virios Therapeutics have been sold short.Short Interest Ratio / Days to CoverVirios Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virios Therapeutics has recently increased by 11.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVirios Therapeutics does not currently pay a dividend.Dividend GrowthVirios Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIRI. Previous Next 2.0 News and Social Media Coverage News SentimentVirios Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Virios Therapeutics this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Virios Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.70% of the stock of Virios Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.05% of the stock of Virios Therapeutics is held by institutions.Read more about Virios Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Virios Therapeutics are expected to decrease in the coming year, from ($0.27) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Virios Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Virios Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVirios Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Virios Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsDid Intel Just Dethrone Nvidia?Intel (INTC) just announced a brand-new AI venture - the Aurora supercomputer. This computer was specifically designed for artificial intelligence and is now the fastest AI-centered computer on the planet. You can get all the details here. About Virios Therapeutics Stock (NASDAQ:VIRI)Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Read More VIRI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIRI Stock News HeadlinesMay 13 at 3:39 PM | markets.businessinsider.comMaintaining Hold on Virios Therapeutics Amid Financial Strains and Clinical Development RisksMay 13 at 3:39 PM | finance.yahoo.comVIRI: Results for Phase 2 Long COVID Trial Expected in 2H24…May 13 at 3:39 PM | finance.yahoo.comVirios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call TranscriptMay 12 at 7:10 PM | uk.investing.comEarnings call: Virios Therapeutics reports on Q1 2024 progressMay 11, 2024 | msn.comVirios Reveals Figures, Corporate UpdateMay 9, 2024 | msn.comVIRI Stock Earnings: Virios Therapeutics Misses EPS for Q1 2024May 9, 2024 | finanznachrichten.deVirios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comVirios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | americanbankingnews.comVirios Therapeutics (VIRI) Scheduled to Post Earnings on ThursdayMay 2, 2024 | globenewswire.comVirios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024April 14, 2024 | finance.yahoo.comVirios Therapeutics, Inc. (VIRI)March 28, 2024 | investing.comVirios Therapeutics seeks global patent for antiviral comboMarch 26, 2024 | globenewswire.comVirios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDFebruary 29, 2024 | investing.comVirios Therapeutics announces salary cuts for employees and boardFebruary 29, 2024 | markets.businessinsider.comVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | markets.businessinsider.comVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesFebruary 28, 2024 | globenewswire.comVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesFebruary 27, 2024 | investing.comVirios Therapeutics Llc (VIRI)February 25, 2024 | msn.comVirios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08February 9, 2024 | morningstar.comVirios Therapeutics Inc Ordinary Shares VIRIFebruary 7, 2024 | finance.yahoo.comVIRI: Moving IMC-2 into Phase 2 Program in Long COVIDFebruary 6, 2024 | finance.yahoo.comFibromyalgia Treatment Market revenue to cross USD 536 Million by 2033, says Research NesterJanuary 23, 2024 | benzinga.comVirios Therapeutics Stock (NASDAQ:VIRI) Dividends: History, Yield and DatesJanuary 22, 2024 | finanznachrichten.deVirios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDSee More Headlines Receive VIRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/14/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VIRI CUSIPN/A CIK1818844 Webwww.virios.com Phone866-620-8655FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-114.70% Return on Assets-103.99% Debt Debt-to-Equity RatioN/A Current Ratio11.60 Quick Ratio11.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book1.91Miscellaneous Outstanding Shares19,260,000Free Float17,005,000Market Cap$7.34 million OptionableOptionable Beta1.87 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Gregory Duncan (Age 58)Chairman & CEO Comp: $559.59kDr. William L. Pridgen M.D. (Age 63)Founder & Director Comp: $35kMs. Angela Walsh (Age 57)CFO, SVP of Finance, Corporate Secretary & Treasurer Comp: $281.28kDr. R. Michael Gendreau M.D. (Age 68)Ph.D., Chief Medical Officer Comp: $420.64kMr. Ralph D. Grosswald M.P.H. (Age 55)Senior Vice President of Operations Comp: $274.69kMs. Carol Duffy Ph.D.Chief Scientific AdvisorMore ExecutivesKey CompetitorsOragenicsNYSE:OGENeFFECTOR TherapeuticsNASDAQ:EFTRCan-Fite BioPharmaNYSE:CANFBionomicsNASDAQ:BNOXVaxxinityNASDAQ:VAXXView All CompetitorsInsidersWilliam PridgenBought 15,335 shares on 8/21/2023Total: $19,935.50 ($1.30/share)Gregory Scott DuncanBought 25,000 shares on 8/17/2023Total: $31,250.00 ($1.25/share)View All Insider Transactions VIRI Stock Analysis - Frequently Asked Questions How have VIRI shares performed in 2024? Virios Therapeutics' stock was trading at $0.5750 on January 1st, 2024. Since then, VIRI stock has decreased by 33.7% and is now trading at $0.3810. View the best growth stocks for 2024 here. When is Virios Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our VIRI earnings forecast. How were Virios Therapeutics' earnings last quarter? Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. When did Virios Therapeutics IPO? Virios Therapeutics (VIRI) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Virios Therapeutics? Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIRI) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
